Article Text

PDF
Treating women with juvenile myoclonic epilepsy
  1. John J Craig1,
  2. Stephen J Hunt2
  1. 1
    Consultant Neurologist, Royal Group of Hospitals, Belfast, UK
  2. 2
    Consultant Neurologist, Royal Group of Hospitals, Belfast, UK
  1. Correspondence to Dr John J Craig, Department of Neurology, Royal Group of Hospitals, Grosvenor Road, Belfast BT12 6BA, UK; john.craig{at}belfasttrust.hscni.net

Abstract

Epilepsy has special implications for women, especially during their childbearing years, and particularly when pregnancy is contemplated. Being aware of the relevant issues is therefore essential. For anyone with juvenile myoclonic epilepsy and other idiopathic generalised epilepsies, valproate is generally regarded as the gold standard treatment against which other antiepileptic drugs are compared. However, information from pregnancy registers consistently show valproate to be associated with the highest risk for major congenital malformations, and studies exploring cognitive and behavioural development of offspring also show that valproate has an adverse impact. This creates a significant headache when trying to choose the “right” drug for most women with a generalised epilepsy syndrome.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Editor’s choice
    Charles Warlow